PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the MASH/NASH field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.71
EASL the International Liver CongressTM 2018,
“LXR inverse agonists reduce steatosis and fibrosis in the STAM™ mouse model but also improve insulin sensitivity in a high fat diet mouse clamp study” Phenex Pharmaceuticals AG
No.70
3rd Annual World Preclinical Congress Europe 2018,
“LXR Inverse Agonists for the Treatment of NASH” Phenex Pharmaceuticals AG
No.69
3rd Annual World Preclinical Congress Europe 2018,
“MTBL0036, a Promising, New Anti-NASH and Antifibrotic Candidate: MTBL0036 showed a decrease in NAFLD Activity score in the STAM™ model” Metabolys, Inc.
No.68
AASLD 2018,
“AXA1125, a Novel Composition of Amino Acids Reprograms the Multifactorial Pathophysiology in NAFLD” Axcella Health Inc.
No.67
AASLD 2018,
“Treatment of Hepatocellular Carcinoma Using 2-Deoxy-D-Glucose Encapsulated in PLGA Nanoparticles in Mice” Kawasaki Medical School
No.66
AASLD 2018,
“Dipeptidyl Peptidase 4 Inhibitors Reduce the Progression of Hepatocellular Carcinoma By Activating T Cell and Natural Killer Cell Chemotaxis in Mice” Kawasaki Medical School
No.65
AASLD 2018,
“Effects of a DPP4 Inhibitor on Progression of Nash-Related Hepatoma and DNA Synthesis Pathway Via p62/Keap1/Nrf2 in a Mouse Model: A Metabolomic Analysis” Kurume University School of Medicine
No.64
AASLD 2018,
“Gemcabene Regulates Hepatic Genes Associated with Inflammation and Fibrosis with Impact on Non-Alcoholic Fatty Liver Disease” Gemphire Therapeutics Inc.
No.63
AASLD 2018,
“CM101, a Novel CCL24 Blocking Antibody, Suppresses Hepatic Injury and Fibrosis In Experimental Models of Nash and Liver Fibrosis” ChemomAb Ltd.
No.62
AASLD 2018,
“Unexpected Antidiabetic Effects Combined with Antifibrotic Activities of LXR Inverse Agonists in Mouse Models of NAFLD/Nash” Phenex Pharmaceuticals AG
No.61
The 78th Scientific Sessions ADA, 2018,
“Canagliflozin, an SGLT2 Inhibitor, Prevents Development of Hepatocellular Carcinoma (HCC) from Nonalcoholic Steatohepatitis (NASH) in a Mouse Model of NASH-HCC Under Diabetic State” Dokkyo Medical University
No.60
The 78th Scientific Sessions ADA, 2018,
“Combination of SGLT2 Inhibitor and Novel Selective PPARα Modulator, Tofogliflozin (Tofo) and Pemafibrate (Pema), Improves Survival Rate in STAM™ Mice as a Diabetic NASH Model” Kowa Company Ltd.
No.59
EASL the International Liver CongressTM 2018,
“Interfering with local fibrotic platelet activation significantly inhibits fibrosis in multiple animal models: suggestions of the importance of the platelet-wound healing axis for fibrosis” Symic Bio, Inc.
No.58
EASL the International Liver CongressTM 2018,
“BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and PRO-C3 in a mouse model of non-alcoholic steatohepatitis” Bristol-Myers Squibb Company
No.57
EASL the International Liver CongressTM 2018,
“LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis” Genomics Institute of the Novartis Research Foundation
No.56
EASL the International Liver CongressTM 2018,
“Clinical-grade human liver mesenchymal stem cells reduce NAS score and fibrosis progression in advanced stage NASH pre-clinical model through immunomodulation” Promethera Biosciences LLC